US Sen. Patty Murray To Grill FDA Commissioner Nominee Stephen Hahn On Prioritizing Science Over Ideology

During a planned confirmation hearing on oncologist Stephen Hahn to become commissioner of the US Food and Drug Administration, a key Senate committee ranking member, Democrat Patty Murray of Washington State, said she will be vetting Hahn on his commitment to promoting science at the agency.

Stephen Hahn, chief medical executive, MD Anderson Cancer Center.
Stephen Hahn, chief medical executive MD Anderson Cancer Center is President Trump's nominee to become FDA Commissioner

Democratic Sen. Patty Murray of Washington, the ranking member of the Senate committee, charged with confirming oncologist Stephen Hahn as the new commissioner of the US Food and Drug Administration (FDA) later this month, promised to vet the physician on prioritizing scientific principles.

A confirmation hearing for Hahn, President Trump's pick to o take over leadership at the FDA who currently serves as chairman of the MD Anderson Cancer Center's radiation department, is...

More from Regulation

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

More from Policy & Regulation